Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis.

@article{AbdelRahman2018SmokingAE,
  title={Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis.},
  author={Omar Abdel-Rahman},
  journal={The clinical respiratory journal},
  year={2018},
  volume={12 5},
  pages={
          1809-1819
        }
}
OBJECTIVES The aim of this study was to assess the potential clinical and biological predictive markers of survival in pretreated advanced NSCLC patients treated with the three PD-(L)1 inhibitors (nivolumab, pembrolizumab and atezolizumab). DATA SOURCE/STUDY SELECTION PubMed database has been searched. The review author extracted relevant information on… CONTINUE READING